Normal Neurochemistry in the Prefrontal and Cerebellar Brain of Adults with Attention-Deficit Hyperactivity Disorder by Dominique Endres et al.
September 2015 | Volume 9 | Article 2421
Original research
published: 28 September 2015
doi: 10.3389/fnbeh.2015.00242
Frontiers in Behavioral Neuroscience | www.frontiersin.org
Edited by: 
Gregory B. Bissonette, 
University of Maryland, USA
Reviewed by: 
Gerry Leisman, 
 O.R.T. Braude College of 
Engineering, Israel 
Rossella Canese, 
Istituto Superiore di Sanità, Italy
*Correspondence:
 Ludger Tebartz van Elst, 
Section for Experimental 
Neuropsychiatry, Department for 
Psychiatry and Psychotherapy, 
University Medical Center Freiburg, 
Hauptstr. 5, Freiburg 79104, 
Germany 
tebartzvanelst@uniklinik-freiburg.de
†Dominique Endres and Evgeniy 
Perlov have contributed equally to 
this work.
Received: 02 June 2015
Accepted: 24 August 2015
Published: 28 September 2015
Citation: 
Endres D, Perlov E, Maier S, Feige B, 
Nickel K, Goll P, Bubl E, Lange T, 
Glauche V, Graf E, Ebert D, 
Sobanski E, Philipsen A and 
Tebartz van Elst L (2015) Normal 
neurochemistry in the prefrontal and 
cerebellar brain of adults with 
attention-deficit hyperactivity 
disorder. 
Front. Behav. Neurosci. 9:242. 
doi: 10.3389/fnbeh.2015.00242
normal neurochemistry in the 
prefrontal and cerebellar brain of 
adults with attention-deficit 
hyperactivity disorder
Dominique Endres1† , Evgeniy Perlov1† , Simon Maier1 , Bernd Feige1 , Kathrin Nickel1 ,  
Peter Goll1 , Emanuel Bubl1 , Thomas Lange2,3 , Volkmar Glauche4 , Erika Graf 5 ,  
Dieter Ebert1 , Esther Sobanski 6 , Alexandra Philipsen1 and Ludger Tebartz van Elst1*
1 Section for Experimental Neuropsychiatry, Department for Psychiatry and Psychotherapy, University Medical Center 
Freiburg, Freiburg, Germany, 2 Department of Radiology, Medical Physics, University Medical Center Freiburg, Freiburg, 
Germany, 3 Freiburg Institute for Advanced Studies, Albert-Ludwigs-University, Freiburg, Germany, 4 Department of 
Neurology, University Medical Center Freiburg, Freiburg, Germany, 5 Clinical Trials Unit, University Medical Center Freiburg, 
Freiburg, Germany, 6 Clinic for Psychiatry and Psychotherapy, Central Institute for Mental Health Mannheim, Mannheim, 
Germany
Attention-deficit hyperactivity disorder (ADHD) is a common neurodevelopmental dis-
order. In an attempt to extend earlier neurochemical findings, we organized a magnetic 
resonance spectroscopy (MRS) study as part of a large, government-funded, prospec-
tive, randomized, multicenter clinical trial comparing the effectiveness of specific psycho-
therapy with counseling and stimulant treatment with placebo treatment (Comparison of 
Methylphenidate and Psychotherapy Study). We report the baseline neurochemical data 
for the anterior cingulate cortex (ACC) and the cerebellum in a case–control setting. For 
the trial, 1,480 adult patients were contacted for participation, 518 were assessed for 
eligibility, 433 were randomized, and 187 were potentially eligible for neuroimaging. The 
control group included 119 healthy volunteers. Single-voxel proton MRS was performed. 
In the patient group, 113 ACC and 104 cerebellar spectra fulfilled all quality criteria for 
inclusion in statistical calculations, as did 82 ACC and 78 cerebellar spectra in the 
control group. We did not find any significant neurometabolic differences between the 
ADHD and control group in the ACC (Wilks’ lambda test: p = 0.97) or in the cerebellum 
(p = 0.62). Thus, we were unable to replicate earlier findings in this methodologically 
sophisticated study. We discuss our findings in the context of a comprehensive review 
of other MRS studies on ADHD and a somewhat skeptical neuropsychiatric research 
perspective. As in other neuropsychiatric disorders, the unclear nosological status of 
ADHD might be an explanation for false-negative findings.
Keywords: attention-deficit hyperactivity disorder, Mrs, glutamate, anterior cingulate cortex, cerebellum, 
nosology
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introduction
Attention-deficit hyperactivity disorder (ADHD) is a common 
and often debilitating disorder that has received increasing 
public and scientific attention. In adulthood, the prevalence 
rates are estimated at 2–4% (Biederman, 2005; Philipsen et al., 
2008). According to the criteria outlined in the Diagnostic and 
Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), 
there are three presentations of ADHD: the inattentive subtype 
(iADHD), the hyperactive-impulsive subtype (hADHD), and the 
combined subtype (cADHD).1 The dopaminergic system seems 
to play a central role in the pathophysiology of ADHD (Philipsen 
et al., 2008). Treatment options for adult ADHD include pharma-
cological interventions (Castells et al., 2011) and psychotherapy 
(Philipsen, 2012). However, because evidence of the efficacy of 
these methods in adults is sparse, the treatment options require 
further investigation (Volkow and Swanson, 2013).
The cOMPas study
In order to investigate treatment options for adult ADHD, the 
Comparison of Methylphenidate and Psychotherapy Study 
(hereafter the COMPAS study), a prospective, double-blind, 
placebo-controlled, multicenter clinical trial, was funded by the 
German Federal Ministry of Education and Research (BMBF: 
ADHD-NET: 01GV0605, 01GV0606) between 2006 and 2013. 
Using a factorial four-arm design, the COMPAS study compared 
the efficacy of cognitive behavioral group psychotherapy to that 
of clinical management in combination with methylphenidate 
(MPH) or placebo (Philipsen, 2008). As an integral part of the 
COMPAS study in the present magnetic resonance spectroscopy 
(MRS) study, we aimed to assess the neurochemical neuronal 
health of enrolled patients and to obtain evidence of putative 
dopaminergic dysfunction in measuring glutamate signals with-
out exposure to radiation.
Magnetic resonance spectroscopy
Magnetic resonance spectroscopy is a unique, non-invasive 
method of measuring different metabolites in the human 
brain. Single-voxel spectroscopy (SVS) is the most established 
method and allows an absolute quantification of the following 
neurometabolites: glutamate (Glu) and glutamine (Gln) and the 
combined Glu and Gln signal (Glx); phosphocholine (PCh) and 
glycerophosphorylcholine (GPC) and the combined total choline 
signal (t-Cho); and N-acetylaspartate (NAA), creatine (Cre), and 
myo-Inositol (mI). Glu is the major excitatory neurotransmitter 
in the human brain. Gln is the precursor and storage form of 
Glu in astrocytes. The activity of the glutamate system is closely 
interwoven with dopaminergic neurotransmission. NAA is 
regarded as a marker of overall neuronal and axonal integrity. 
t-Cho indicates cell-membrane turnover. Cre is a marker of brain 
energy metabolism. Lastly, mI is a glial marker as well as a part 
of the phosphatidylinositol second messenger system (Ross and 
Bluml, 2001). Since MRS is capable of quantifying all of these 
neurometabolites under specific conditions, it could provide a 
1 www.dsm5.org
comprehensive assessment of the neurochemical health of the 
brain (Perlov et al., 2009).
Previous Mrs Findings regarding aDhD
We performed a comprehensive review of the MRS literature on 
ADHD on the basis of a PubMed search using the search terms 
“ADHD” and “spectroscopy.” We identified 416 hits (on May 30, 
2015) that were individually screened for content. Excluding 
methodological papers, reviews, and case reports, we identified 
32 MRS studies on ADHD. All of these studies are presented in 
Table 1, and we discuss this literature in detail in the discussion 
section of the paper. During the finalization of our study proto-
col (2006), there was first evidence – albeit limited – of altered 
fronto-striatal NAA signals (Hesslinger et  al., 2001; Jin et  al., 
2001) and increased glutamate signals (MacMaster et al., 2003; 
Courvoisie et al., 2004), which were reduced under medication 
with stimulants (Carrey et al., 2002, 2003).
rationale of Our study
Based on the evidence available during the finalization of the 
study protocol, we hypothesized that we would find altered 
fronto-striatal Glx and NAA signals in adult patients with ADHD 
as indirect evidence of dopaminergic dysfunction. Following 
the initial  measurements of the striatum, which had very poor 
data quality, we abstained from our initial intent to measure the 
striatum and instead focused on the anterior cingulate cortex 
(ACC) and cerebellum. We adopted this approach because we 
already had data – which at that time was unpublished – pointing 
to glutamatergic abnormalities in these volumes of interest (VOIs) 
with decreased Glu/Cre ratios in the right pregenual ACC and 
increased Glu/Cre ratios in the left cerebellar hemisphere (Perlov 
et al., 2007, 2009, 2010).
Materials and Methods
As an integral part of the multicenter COMPAS study, the imag-
ing study received approval from the leading ethics committee 
(Faculty of Medicine, Freiburg University, 217/06) and authoriza-
tion from the relevant German authorities (EudraCT No.: 2006-
000222-31). Prior to beginning the study, the trial was registered 
with Current Controlled Trials.2 The methods, including the study 
design, endpoints, patient enrollment, and characteristics of the 
clinical study sample, have been described in detail previously 
(Philipsen et al., 2010, 2014). The study protocol is published in 
German on the Internet (Philipsen, 2008). All participants gave 
written consent for their participation in the imaging project.
Patient assessment
The patient assessment took place between January 2007 and 
August 2010. The diagnostic procedure has been described in detail 
in two previous papers (Philipsen et al., 2010, 2014). All patients 
were stimulant-free for at least 6 months prior to scanning. Table 2 
provides an overview of the screening process and the details of 
the MRS substudy’s selection procedure. Inclusion and exclusion 
criteria for the ADHD group are listed in Supplemental Table 1. 
2 www.isrctn.com/ISRCTN54096201
TaBle 1 | summary of previous Mrs studies on aDhD.
study Population n (aDhD/controls) Methods region(s) results
1. Hesslinger et al. (2001) Adults; iADHD, cADHD 10/5 2 T, SVS, 1H-MRS (PRESS) DLPFC le
Striatum le
NAA ↓ in cADHD vs. control/iADHD
↔
2. Jin et al. (2001) Children 12/10 1.9 T, SVS, 1H-MRS (PRESS); MPH once Striatum le
Striatum ri
NAA/Cre ↓
NAA/Cre ↓, t-Cho/Cre ↑; MPH-once 
without effect
3. Carrey et al. (2002) Children 4/0 1.5 T, SVS, 1H-MRS (PRESS); before and 
after MPH/AM
Striatum le
PFC ri
Glx/Cre ↓ under MPH + AM
Glx/Cr ↓ only under AM
4. MacMaster et al. (2003) Children 9/9 1.5 T, SVS, 1H-MRS (PRESS) Striatum le
PFC ri
↔
Glx/Cre ↑
5. Carrey et al. (2003) Children; iADHD, cADHD 14/0 1.5 T, SVS, 1H-MRS (PRESS); before and 
after MPH (4)/AM (3)/Dexedrine (7)
Striatum le
PFC ri
Glx/Cre ↓ under medication
↔
6. Yeo et al. (2003) Children; hADHD, iADHD 23/24 1.5 T, SVS, 1H-MRS (STEAM) Frontal ri ↔
7. Courvoisie et al. (2004) Children; hADHD 8/8 1.5 T, SVS, 1H-MRS (STEAM) Frontal ri
Frontal le
Glu/Cre ↑, NAA/Cre ↑, t-Cho/Cre ↑
Glu/Cre ↑
8. Sparkes et al. (2004) Children 8/6 1.5 T, SVS, 1H-MRS (PRESS) Striatum le
PFC ri
↔
↔
9. Fayed and Modrego (2005) Children 8/12 1.5 T, SVS, 1H-MRS (PRESS) Centrum semiovale le NAA/Cre ↑
10. Sun et al. (2005) Children; iADHD, cADHD 20/10 1.9 T, SVS, 1H-MRS (PRESS) Nucleus lenticularis ri
Nucleus lenticularis le
NAA/Cre ↓ in cADHD (vs. iADHD and 
controls)
NAA/Cre ↓ in cADHD (vs. controls)
11. Moore et al. (2006) children 15 (+8 patients with 
comorbid bipolar 
disorder)/7
1.5 T, sVs, 1h-Mrs (sTeaM) acc glx/mi ↑ (vs. controls/comorbid 
bipolar disorder), glx/cre ↑ (vs. 
comorbid bipolar disorder)
12. Stanley et al. (2006) Children; iADHD, cADHD 10/15 1.5 T, multivoxel 31-P-MRS PFC
Basal ganglia
Free-PME ↓
Free-PME ↓, free-PME/free-PDE ↓
Superior temporal ↔
13. Fayed et al. (2007) Children 22/8 1.5 T, SVS, 1H-MRS (PRESS) Centrum semiovale le
PFC ri
NAA/Cre ↑
NAA/Cre ↑
14. Carrey et al. (2007) Children; cADHD 13/10 1.5 T, SVS, 1H-MRS (PRESS); before and 
after MPH 
Striatum le
PFC ri
Occipital lobe
Glx ↑, Cre ↑; Cre ↓ after MPH
↔
↔
15. Perlov et al. (2007) adults 28/28 1.5 T, csi, 1h-Mrs (Press) acc ri
acc le
glx/cre ↓
↔
16. colla et al. (2008) adults 15/10 1.5 T, csi, 1h-Mrs (Press) acc both sides t-cho ↑
(Continued)
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study Population n (aDhD/controls) Methods region(s) results
17. Stanley et al. (2008) Children; iADHD, cADHD 31/36 1.5 T, multivoxel 31-P-MRS Basal ganglia
Inferior parietal
Superior temporal
Posterior white matter
Occipital lobe
free-PME ↓
Free-PME ↑, free-PME/free-PDE ↑
↔
↔
↔
18. Kronenberg et al. (2008) adults 7/0 1.5 T, csi, 1h-Mrs (Press); before and 
after MPh
acc both sides t-cho ↓, naa ↑ after MPh
19. Ferreira et al. (2009) Adults; iADHD, cADHD 19/12 1.5 T, SVS, 1H-MRS (PRESS) VMPFC ri
VMPFC le
Thalamus ri
Thalamus le
Striatum ri
Striatum le
mI/Cre ↓ (in cADHD vs. controls)
↔
↔
t-Cho/Cre ↑ (in cADHD vs. iADHD)
↔
Glx/Cre ↑ (in cADHD vs. iADHD/
controls)
20. Yang et al. (2010) Children; cADHD, iADHD 15/22 1.5 T, SVS, 1H-MRS (PRESS) PFC ri
PFC le
Cre ↓, NAA/Cr ↑
↔
21. soliva et al. (2010) children; iaDhD, haDhD, 
caDhD
17/17 1.5 T, sVs, 1h-Mrs (Press) DlPFc ri
cerebellum le
cre ↓
mi ↓, naa ↓, cre ↓
22. Perlov et al. (2010) adults; caDhD 30/30 1.5 T, csi, 1h-Mrs (Press) cerebellum le
cerebellum ri
cerebellar vermis
glx/cre ↑
↔
↔
23. Dramsdahl et al. (2011) Adults; hADHD, iADHD, cADHD 29/38 3 T, SVS, 1H-MRS (PRESS) Frontal le
Frontal ri
Glu/Cre ↓
↔
24. hammerness et al. (2012) children 10/12 4 T, sVs, 1h-Mrs (Press); before and 
after MPh
acc both sides ↔, no significant changes under 
MPh
25. Edden et al. (2012) Children; iADHD, cADHD 13/19 3T, SVS, 1H-MRS (PRESS) Motor cortex le GABA↓
26. Wiguna et al. (2012) children; iaDhD, caDhD 21/0 1.5 T, sVs, 1h-Mrs; before and after 
MPh
PFc le
PFc ri
naa/cre ↑, glu/cre ↓, t-cho/cre ↓, 
mi/cr ↓ after MPh
naa/cre ↑, glu/cre ↓, t-cho/cre ↓ 
after MPh
TaBle 1 | continued
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study Population n (aDhD/controls) Methods region(s) results
27. arcos-Burgos et al. (2012) children, adults 14/20 1.5 T, csi, 1h-Mrs (Press) striatum ri, striatum 
le, corpus callosum 
(splenium), acc ri, 
acc le, Mcc ri, Mcc 
le, Pcc ri, Pcc le, 
thalamus ri (lateral and 
medial), thalamus le 
(lateral and medial), 
and cerebellar vermis
Pcc ri showed significant 
differences of the glx/cr ratio 
density distribution
28. Tafazoli et al. (2013) Children; iADHD, cADHD 13/13 1.5 T, CSI, 1H-MRS (PRESS) DLPFC re
DLPFC li
NAA ↓, Cre ↓, t-Cho ↓, mI ↓
↔
29. Benamor (2014) children; haDhD, iaDhD, 
caDhD
102 (57 medicateda, 45 
unmedicated)/38
1.5 T, sVs, 1h-Mrs (Press) PFc le
PFc ri
striatum le
striatum ri
cerebellum le
t-cho/cre ↓ in unmedicated aDhD 
(vs. medicated aDhD and controls)
↔
naa/cre ↑ in unmedicated aDhD 
(vs. medicated aDhD and controls)
↔
glx/cre ↑ in unmedicated aDhD 
(vs. medicated aDhD and controls)
30. Maltezos et al. (2014) Adults; iADHD, cADHD 40 (16 medicatedb, 24 
unmedicated)/20
1.5 T, SVS, 1H-MRS (PRESS) Basal ganglia le
DLPFC le
Medial parietal lobe le
Glx ↓, Cre ↓, NAA ↓
Cre ↓
↔
31. Husarova et al. (2014) Children; cADHD 21/0 1.5 T, SVS, 1H-MRS (PRESS); before and 
after MPH/AM
DLPFC le
DLPFC ri
Anterior semioval center le
Anterior semioval center ri
NAA and NAA/Cre ↓ after AM
t-Cho/Cre ↑ after AM
Glx ↑ and Glx/Cre ↑ after MPH
↔
32. Wiguna et al. (2014) Children; cADHD and iADHD 21/0 1.5 T, SVS, 1H-MRS; before and after MPH Amygdala le
Amygdala ri
Glu/Cre ↓ after MPH
Glu/Cre ↓ after MPH
Cre, creatine; t-Cho, phosphorylcholine + glycerylphosphorylcholine; Glu, glutamate; Glx, glutamate + glutamine; NAA, N-acetylaspartate; mI, myo-Inositol; le, left; ri, right; ↑, increase in ADHD; ↓, decrease in ADHD; ↔, no 
metabolite differences between groups; MPH, methylphenidate; AM, atomoxetine; iADHD, inattentive ADHD subtype; cADHD, combined ADHD subtype; hADHD, hyperactive ADHD subtype; PRESS, point-resolved spectroscopy; 
STEAM, stimulated echo acquisition method; T, Tesla; SVS, single-voxel spectroscopy; CSI, chemical shift imaging; 31-P-MRS, phosphorus magnetic resonance spectroscopy; 1H-MRS, proton magnetic resonance spectroscopy; 
DLPFC, dorsolateral prefrontal cortex; ACC, anterior cingulate cortex; PCC, posterior cingulate cortex; MCC, medial cingulate cortex; free-PME, freely mobile membrane phospholipid precursors; free-PDE, freely mobile membrane 
phospholipid breakdown products.
Studies measuring the anterior cingulate cortex or cerebellar regions are in bold type.
aMPH or amphetamine.
bMPH or dextro-amphetamine.
TaBle 1 | continued
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The MRS sample was restricted to two study centers, one at 
Freiburg and one at Mannheim, in order to avoid scanner vari-
ance by performing measurements with only one MRI scanner 
at the Freiburg center. For this study, 113 ACC spectra and 104 
cerebellar spectra fulfilled all the subsequent quality criteria for 
inclusion in statistical calculations.
assessment of control subjects
The healthy control group was recruited via public announce-
ments. We took great care to exclude relevant neuropsychiatric 
conditions and to provide psychometric assessments of our con-
trol subjects. The assessment instruments and exclusion criteria 
are illustrated in Supplemental Table 2. We were able to keep 82 
ACC and 78 cerebellum data sets that fulfilled all quality criteria.
Matching Procedure
We attempted to select controls such that the distributions of 
demographic variables in controls would resemble those in 
patients. However, because many data sets had to be excluded 
after the measurements for data quality reasons, the final control 
sample was not fully matched. We considered but ultimately 
decided against a secondary matching procedure, in which we 
could have selected a smaller control sample from the pool of 
available control data that would have been matched with respect 
to all demographic data. Instead, we decided to include all the 
control data that fulfilled the methodological quality criteria, and 
we accounted for statistically significant differences in demo-
graphic variables by including the respective factors as covariates 
in the linear model to compare patients with controls.
Data acquisition and analysis
Magnetic resonance spectroscopy measurement and analysis were 
performed following a method established in previous studies 
(Tebartz van Elst et al., 2014a,b). All measurements were obtained 
at the University of Freiburg on a 3-Tesla whole-body scanner 
(Siemens Magnetom Trio a TIM system; Erlangen, Germany) using 
a 12-channel head-coil for signal reception. First, a T1-weighted 
3D data set was recorded using a magnetization-prepared 
rapid-acquisition gradient echo (MPRAGE) sequence with the 
following parameters: field of view (FOV) = 256 mm × 256 mm, 
repetition time (TR) = 2200 ms, echo time (TE) = 4.11 ms, flip 
angle = 12°, and voxel size = 1 mm × 1 mm × 1 mm. For spectro-
scopic measurements, voxels were placed in the pregenual ACC 
(16 mm × 25 mm × 20 mm) and in the center of the left cerebel-
lar hemisphere (20 mm × 20 mm × 20 mm). A point-resolved 
spectroscopy (PRESS) sequence with a TR of 3000 ms and a TE 
of 30 ms was used. For the absolute quantification of metabolites, 
we also acquired a non-water-suppressed reference spectrum. 
TaBle 2 | aDhD and healthy control collective and reasons for exclusion.
1480 patients contacted for study participation healthy controls were recruited via announcements 
on the campus and assessed as presented in 
supplemental Table 2
↓ (→ 962 ineligible or not interested)
518 patients assessed for eligibility
↓ (→ 274 patients from Berlin, Würzburg, Homburg, 
Essen, and Mainz)
244 patients from Freiburg and Mannheim
↓ (→ 57 ineligible or not interested in MRI substudy)
187 patients potentially eligible for Mri substudy 119 healthy controls potentially eligible for Mri study
reasons for further exclusion anterior cingulate cortex cerebellum anterior cingulate cortex cerebellum
Missing, incomplete, or pathological 
psychometric documentation
8 8 18 18
Study participation canceled, consent 
withdrawal, or non-compliancea
14 14 0 0
Metal implant 8 8 0 0
Claustrophobia 9 9 0 0
Abortion of measurement 5 5 3 3
Different voxel position 0 12 0 2
Failure in measurement protocol, data 
transfer, or data analysis
12 11 6 7
Bad spectral quality 8 6 4 5
New diagnosis of neurocytoma 1 1 0 0
Post hoc information about exclusion criteria 9 9 6 6
113 high-quality acc and 104 high-quality 
cerebellar spectra for statistical analysis
82 high-quality acc and 78 high-quality cerebellar 
spectra for statistical analysis
ACC, anterior cingulate cortex.aFailure to show up on the measurement dates.
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For spectroscopic analysis, the well-established LCModel (lin-
ear combination of model spectra) algorithm was used. The 
absolute quantification of metabolites (Cre, t-Cho, Glx, NAA, 
and mI) was estimated using an internal water signal reference 
(Provencher, 1993, 2001; Helms, 2008; Tebartz van Elst et  al., 
2014a,b). For further analyses, only spectra with Cramér-Rao 
lower bounds (CRLBs) for the main metabolites <20% were 
included (Provencher, 1993, 2001).3 To estimate the water con-
tent in the VOI, the MPRAGE was segmented into gray matter 
(GM), white matter (WM), and cerebrospinal fluid (CSF), using 
the unified-segmentation approach according to Ashburner 
and Friston (2005) and as implemented in Statistical Parametric 
Mapping, Version 8 (SPM8). For each spectroscopy voxel, the 
partial volumes of GM, WM, and CSF were computed from this 
segmentation. The metabolic concentrations of each VOI were 
correct for the contents of GM, WM, and CSF. Figure  1 sum-
marizes all the details.
statistical analysis
Group comparisons for continuous variables (age, IQ, nicotine 
consumption, and psychometric scores) were performed with 
two-sided independent-sample t-tests. Group comparisons for 
3 www.s-provencher.com/pages/lcmodel.shtml
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FigUre 1 | Mri data acquisition and spectroscopic analyses. MPRAGE, magnetization-prepared rapid-acquisition gradient echo; FOV, field of view; TR, 
repetition time; TE, echo time; ACC, anterior cingulate cortex; PRESS, point-resolved spectroscopy; LCModel, linear combination of model spectra; Cre, creatine; 
t-Cho, phosphorylcholine + glycerylphosphorylcholine; Glx, glutamate + glutamine; NAA, N-acetylaspartate; mI, myo-Inositol; ppm, parts per million; CRLBs, 
Cramér-Rao lower bounds; SPM8, Statistical Parametric Mapping – Version 8; GM, gray matter; WM, white matter; CSF, cerebrospinal fluid.
gender were calculated using Pearson’s two-sided chi-squared 
test. For primary analysis, the neurometabolite concentrations 
of the patient and control groups were compared using a mul-
tivariate analysis of covariance and employing a general linear 
model (MANCOVA). The concentrations of neurometabolites 
were chosen as dependent variables. Of the possible influencing 
factors considered – age (Kaiser et al., 2005), gender, IQ (Jung 
et  al., 1999), and nicotine consumption (Domino, 2008)  –  all 
except gender differed significantly between the ADHD and 
control groups (p < 0.05). Therefore, these values were included 
as covariates. To test for an overall group effect across all five 
neurometabolites, a multivariate Wilks’ lambda test was per-
formed. Group differences per single neurometabolite concen-
tration were tested and estimated with the confidence interval 
from the linear MANCOVA model, adjusting for the imbalanced 
influencing factors. Next, the ADHD subtypes were compared 
with the control groups using the same MANCOVA approach 
and employing a multivariate Wilks’ lambda test. Correlation 
analyses were performed using the Spearman correlation coef-
ficient. For overall and single-group differences in neurome-
tabolite concentrations, the level of significance was corrected 
for multiple tests using the Bonferroni approach (p <  0.025, 
because we measured two regions; 97.5% confidence intervals). 
For all subgroup and correlation analyses, we did not correct for 
multiple comparisons (p < 0.05 as the criterion of significance).
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results
Demographic and Psychometric Data
Table 3 summarizes the demographic and psychometric data for 
the ADHD and control groups following the exclusion of all com-
promised data sets. In both the ACC and the cerebellum samples, 
the patient and control groups significantly differed in age, IQ, 
and nicotine consumption, but not in gender. As expected, the 
psychometric scores for ADHD symptoms and depressiveness 
were significantly higher in the patient group.
Mrs results
Table 4 summarizes the spectroscopic results. Scatterplots of all 
individual metabolite concentrations, with means and 95% con-
fidence intervals, are presented in Figure 2. Subgroup analyses 
are presented in Table 5 and correlation analyses are presented 
in Supplemental Table 3.
Anterior Cingulate Cortex
A Wilks’ lambda test found no significant overall between-group 
group differences for the five neurometabolite concentrations in 
the ACC (p = 0.97). Furthermore, none of the metabolite concen-
trations were found to differ significantly between patients and 
controls. The inattentive and combined ADHD subtypes did not 
differ significantly from the control groups. A significant negative 
correlation between t-Cho and subclinical depression (measured 
via the Beck Depression Inventory score) was found (p = 0.0006).
Cerebellum
No overall metabolite differences between groups were found 
(Wilks’ lambda: p =  0.62) in the cerebellar VOI as well. Again, 
no differences in any of the five single metabolites were detected. 
Moreover, the subgroup analyses did not reveal any significant dif-
ferences. The correlation analysis showed a discrete negative corre-
lation between the mI signal and nicotine consumption (p = 0.04).
Discussion
The main finding of this large study is the absence of any significant 
differences between patients and controls. We could not replicate 
earlier findings and could not confirm our working hypothesis 
regarding altered NAA and glutamate signals. In fact, we did not 
find evidence of any neurochemical abnormality.
False-negative Finding?
The issue of a potentially false-negative finding can be addressed 
by looking at the confidence intervals. Table 4 illustrates that all 
lower and upper bounds of the 97.5% confidence intervals for 
the estimated mean differences for all metabolites are no more 
than 0.6 standard deviations below or above 0. We can thus 
exclude even moderate differences between patients and controls 
corresponding to effect sizes of 0.6 and greater. This observation 
supports the notion that we have produced true negative results.
comparison to Previous studies
How does this compare to previous research? We performed 
a comprehensive review of the MRS literature on ADHD (see 
Table 1). The respective results illustrate that our negative find-
ing is in line with the majority of previous reports. While several 
earlier studies  –  including our own (Perlov et  al., 2007, 2009, 
2010) – did find significant differences in Glx signals and other 
neurometabolites, no clear pattern of signal change emerged 
across different studies.
What might be the reasons for these discrepant findings? 
Table  1 and Supplemental Table 4 illustrate that the sample 
sizes of several previous studies were rather small. Furthermore, 
differences in findings might be due partially to differences 
in scanning techniques, acquisition protocols, analytical 
algorithms, and sample-selection criteria. In previous studies, 
patient samples differed in terms of age, subtype, medication, 
and comorbidity.
TaBle 3 | Demographic and psychometric data.
anterior cingulate cortex cerebellum
aDhD (n = 113) controls (n = 82) p-valuea aDhD (n = 104) controls (n = 78) p-valuea
Mean ± sD/n Mean ± sD/n Mean ± sD/n Mean ± sD/n
Age 33.9 ± 9.9 36.8 ± 10.1 0.05 34.2 ± 10.2 37.8 ± 10.2 0.02
Gender 57M:56F 40M:42F 0.82 52M:52F 39M:39F 1.0
Intelligence quotientb 113.5 ± 15.7 120.2 ± 16.8 0.005 113.4 ± 16.0 119.6 ± 16.9 0.01
Nicotine (cigarettes/day) 5.7 ± 10.6 1.4 ± 3.8 <0.001 5.5 ± 9.8 1.4 ± 3.9 <0.001
Wender Utah Rating Scale 
(Retz-Junginger et al., 2002)
40.2 ± 8.8 8.4 ± 7.1 <0.001 40.3 ± 8.8 8.2 ± 7.2 <0.001
CAARS-ADHD-Index 
(Conners, 1999)
66.8 ± 11.9 39.5 ± 7.0 <0.001 66.7 ± 12.2 39.4 ± 6.7 <0.001
Beck Depression Inventory 
score (Hautzinger, 2006)
11.9 ± 8.0 2.3 ± 3.3 <0.001 11.4 ± 8.1 2.5 ± 3.4 <0.001
ADHD subtype 54 iADHD, 4 hADHD,c 
55 cADHD
No 47 iADHD, 4 hADHD,c 
53 cADHD
No
SD, standard deviation; M, male; F, female; CAARS, Conners Adult ADHD Rating Scales – self report: long version; iADHD, inattentive subtype; hADHD, hyperactive-impulsive 
subtype; cADHD, combined subtype.
ap-value: to test for differences between groups.
bMeasured by the Multiple-Choice Vocabulary Intelligence Test (Lehrl et al., 1995).
cThe hyperactive subtype was added to the combined subtype for all subtype analyses because of the small group size.
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Concerning age, studies on children and adults have to be distin-
guished because children have developing (i.e., dynamically chang-
ing) brains, whereas adult brains’ fundamental neurochemical and 
structural properties are not considered to change in a developmental 
manner. In the present study, we investigated only adult patients; 
therefore, developmental considerations should be negligible. 
Furthermore, the number of medicated patients differed in previous 
studies. In addition to being linked to short-term neurometabolic 
changes in some studies (Carrey et al., 2002; MacMaster et al., 2003; 
Wiguna et al., 2012; Husarova et al., 2014), MPH exposure may also 
cause long-term changes (Nakao et al., 2011; Frodl and Skokauskas, 
2012). In our study, patients had gone at least 6  months without 
ADHD-specific medication. Therefore, it is unlikely that the normal-
izing effects of ADHD medication could explain our negative findings. 
The influence of comorbid diseases must also be taken into account 
because most psychiatric comorbidities might be related to changes 
in neurometabolism. In this study, relevant psychiatric comorbidi-
ties, such as present depressive disorder or other first-axis disorders, 
served as exclusion criteria. In summary, there is little evidence to 
suggest that age, medication, or the pathophysiology of comorbid 
neuropsychiatric disorders have contributed to our findings.
sample selection and Mrs
This study was an integral part of the abovementioned COMPAS 
study. The sample selection followed strict standards (Philipsen 
et al., 2010, 2014). Only primary ADHD cases were included, and 
evidence of organic cerebral diseases led to exclusion. Therefore, 
our results cannot be generalized to patients with secondary 
forms of ADHD. We decided against secondary matching proce-
dures and included all participants with good data quality in our 
statistical analyses. In doing so, we generated a large, carefully 
characterized, and fully transparent data set that minimized the 
risk of false-positive findings due, for example, to inadequate 
selection of controls. We methodically used the well-established 
and well-evaluated single-voxel proton spectroscopy to measure 
the absolute neurometabolite concentrations with an investigator-
independent method (Tebartz van Elst et al., 2014a,b).
neurochemical Perspective
Our data compel us to conclude that the brains of adult ADHD 
patients are essentially normal from a neurochemical perspective. 
Of course, we cannot generalize this finding to regions of the brain 
other than those that we measured. Furthermore, we cannot con-
clude that this proposition is true for children with ADHD. It might 
be the case that the reported abnormalities in children were true and 
that the respective neurochemical abnormalities linked to ADHD 
have normalized during maturation. However, this interpretation is 
not supported by our study because most of the clinical symptoms of 
ADHD were still present in our adult patient sample. Alternatively, 
in this scenario, one could conclude that the reported neurochemi-
cal abnormalities are not necessarily linked to the presence of the 
clinical ADHD symptoms. However, it is important to recognize 
that neurochemical processes measured by MRS are only a part of 
brain functioning. They are based on anatomical structures, which 
are organized in fronto-basal loops. The structural dysfunction of 
the fronto-striato-thalamo-frontal circuits plays a key role in the 
pathogenesis of ADHD (Perlov et  al., 2009). These circuits have 
a common anatomical organization, beginning in the prefrontal 
cortex, innervating the striatum and the pallidum/substantia nigra, 
and ending in projections back in the frontal brain (Tekin and 
Cummings, 2002). For example, the ACC subcortical circuit plays 
an important role in motivation. The model of circuits illustrates 
that different neurochemical or anatomical lesions may lead to the 
same symptoms and that vice  versa the same symptoms can be 
induced by different lesions (Tebartz van Elst and Perlov, 2013).
neuropsychiatric research Perspective
The alternative interpretation involves a greater degree of skepti-
cism about the scientific process as a whole. As in many other 
areas of neuropsychiatric research, initially promising findings 
cannot be replicated in large and methodologically sound stud-
ies. We reported relevant neurochemical findings regarding 
adult ADHD in both VOIs measured here. As illustrated in 
Table  1, the sample sizes of our recent studies compared well 
to those of other studies, and the methodology of these stud-
ies was also sound. However, we were not able to replicate our 
earlier findings – or those of others – in this large study. What 
can we conclude from this observation? First of all, it somewhat 
questions the notion that true abnormalities reported in children 
and adolescents might have normalized during the process of 
growing up, because in the area of adult research, we ourselves 
had reported significant findings in studies with a sample size of 
about 30 patients and controls that we are now unable to replicate 
(Perlov et al., 2007, 2010).
TaBle 4 | spectroscopic findings in the pregenual acc and the cerebellum (iU).
anterior cingulate cortex cerebellum
aDhD (n = 113) 
unadjusted 
mean ± sD
controls 
(n = 82) 
unadjusted 
mean ± sD
adjusted  
difference  
(97.5% ci)a
MancOVa test 
for difference 
(Wilks’ lambda 
test: p = 0.97)a
aDhD  
(n = 104) 
unadjusted 
mean ± sD
controls 
(n = 78) 
unadjusted 
mean ± sD
adjusted  
difference  
(97.5% ci)a
MancOVa test 
for difference 
(Wilks’ lambda 
test: p = 0.62)a
Cre 8.86 ± 1.32 8.84 ± 1.27 0.15 (−0.29 to 0.59) p = 0.43 9.28 ± 1.17 9.28 ± 0.81 0.03 (−0.34 to 0.40) p = 0.85
t-Cho 2.24 ± 0.40 2.27 ± 0.39 0.04 (−0.09 to 0.16) p = 0.52 2.29 ± 0.34 2.26 ± 0.27 0.05 (−0.06 to 0.16) p = 0.27
Glx 16.17 ± 2.37 16.05 ± 2.31 0.32 (−0.49 to 1.12) p = 0.38 10.78 ± 1.84 10.88 ± 1.22 −0.24 (−0.81 to 0.33) p = 0.35
NAA 11.41 ± 1.56 11.38 ± 1.24 0.17 (−0.33 to 0.66) p = 0.44 9.04 ± 0.94 9.08 ± 0.68 −0.02 (−0.32 to 0.27) p = 0.86
mI 6.13 ± 1.05 6.06 ± 0.96 0.10 (−0.25 to 0.45) p = 0.51 4.86 ± 0.87 4.99 ± 0.85 −0.10 (−0.41 to 0.21) p = 0.45
SD, standard deviation; CI, confidence interval; Cre, creatine; t-Cho, phosphorylcholine + glycerylphosphorylcholine; Glx, glutamate + glutamine; NAA, N-acetylaspartate; mI, myo-Inositol.
aMANCOVA, multivariate analysis of covariance using the covariates age, IQ, and nicotine consumption.
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Altogether, the essentially negative findings of this large study 
support a more prudent approach to interpreting data from small 
studies. Recently, a series of papers addressed this problem in 
the context of biomedical research (Al-Shahi Salman et  al., 
2014; Chalmers et  al., 2014; Chan et  al., 2014; Glasziou et  al., 
2014; Ioannidis et al., 2014; Macleod et al., 2014). Particularly 
in imaging research, numerous studies have small and some-
times ill-defined patient samples. The issue of replication is 
often neglected. Positive findings from different studies are 
often used as evidence supporting the findings of the study of 
interest. However, the implicit negative results of many other 
studies are neglected. For example, we ourselves summarized 
all the previous MRS studies on ADHD (Table 1) and focused 
on their positive findings. However, every study that does not 
repeat the findings of previous studies must be regarded as a non-
replication. The fact that most papers focus on positive findings 
blurs this view. Meta-analyses are one way to pool respective 
data. However, as in this case, they tend to generate negative find-
ings, particularly if a cross-meta-analytical perspective is taken. 
Our first meta-analysis of MRS findings in ADHD showed an 
increase in only the t-Cho signal in the striatum and right frontal 
lobe of children and in the ACC of adult patients (Perlov et al., 
2009). A recent meta-analysis described only an increased NAA 
signal in the medial prefrontal cortex of children and showed 
no abnormalities in the adult ADHD group (Aoki et al., 2013). 
From a cross-meta-analytical perspective, we have to conclude 
that no specific patterns of MRS abnormalities emerged upon 
observation of the results of both papers.
The nosology Problem
Another possible reason for a false-negative finding has to be con-
sidered at this point. ADHD is generally understood as a disorder 
of heterogeneous etiologies, which means that it is quite possible 
that as a result of generating large patient samples, different etio-
logical ADHD subgroups will be examined within one study group. 
For practical reasons, it might well be the case that in generating 
large study samples, the likelihood of diversifying the study group 
increases from an etiological point of view. For example, when organ-
izing large multicenter study groups, it is more likely that different 
diagnosticians will be involved in the study process even if the study 
protocol is, like ours, very prudent. For this reason, large studies 
might be more vulnerable to diverse underlying etiologies than stud-
ies with smaller samples generated by one or a few diagnosticians.
The issue of ADHD subforms and subtypes must also be consid-
ered. All possible secondary forms of ADHD were excluded from 
our study. Primary or secondary forms of ADHD and different 
ADHD subtypes might represent different pathophysiologies (this 
is comparable to autism spectrum disorder as a basic disorder) 
(Tebartz van Elst et al., 2013). We think that progress in neuropsy-
chiatric research in general, and neurobiological ADHD research in 
particular, will be closely linked to the recognition of this nosology 
problem (Tebartz van Elst et al., 2006). If it is true that a purely clini-
cally defined group of ADHD patients represents different etiolo-
gies and cerebral pathophysiologies, then the inclusion of different 
pathophysiologies within one study sample will necessarily lead 
to diverse and contradictory results in different samples (Tebartz 
van Elst et al., 2014a,b). The larger and more pathophysiologically 
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FigUre 2 | Metabolite signals presented as scatterplots. CI, 95% confidence interval; Cre, creatine; t-Cho, phosphorylcholine +glycerylphosphorylcholine; 
Glx, glutamate + glutamine; NAA, N-acetylaspartate; mI, myo-Inositol; IU, institutional unit.
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heterogeneous a single study sample is, the more likely it is that 
true signal differences in subgroups of the sample will statistically 
counterbalance each other and result in normal average signals in 
calculations of the means of the overall group. Further studies and 
conceptual work will have to tackle this problem.
conclusion
To date, this is the largest MRS study examining cerebral neuro-
chemistry in ADHD. We were able to demonstrate an essentially 
normal neurochemical profile of the ACC and the cerebellum in 
adult patients without current comorbid psychiatric disorders. 
We were unable to replicate earlier positive findings. Such previ-
ous positive findings might have been linked to small sample 
size, psychiatric comorbidity, or medication effects. However, 
the nosology problem of psychiatry (i.e., disorder categories 
comprise patient subgroups with different pathophysiologies) 
also has to be considered when interpreting the negative findings 
of large neuropsychiatric study samples.
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TaBle 5 | subgroup analyses of spectroscopic findings in the anterior cingulate cortex and cerebellum of the inattentive and combined subtypes and 
controls (iU).
iaDhD (n = 54) 
unadjusted 
mean ± sD
controls 
(n = 82) 
unadjusted 
mean ± sD
adjusted difference 
(95% ci)a
MancOVa test 
for difference 
(Wilks’ lambda 
test: p = 0.99)a
caDhDb 
(n = 59) 
unadjusted 
mean ± sD
controls 
(n = 82) 
unadjusted 
mean ± sD
adjusted difference 
(95% ci)a
MancOVa test 
for difference 
(Wilks’ lambda 
test: p = 0.86)a
anterior cingulate cortex
Cre 8.73 ± 1.39 8.84 ± 1.27 0.10 (−0.38 to 0.58) p = 0.68 8.99 ± 1.25 8.84 ± 1.27 0.23 (−0.21 to 0.68) p = 0.31
t-Cho 2.18 ± 0.45 2.27 ± 0.39 0.01 (−0.14 to 0.15) p = 0.91 2.30 ± 0.34 2.27 ± 0.39 0.08 (−0.05 to 0.20) p = 0.22
Glx 16.04 ± 2.52 16.05 ± 2.31 0.30 (−0.59 to 1.18) p = 0.51 16.28 ± 2.25 16.05 ± 2.31 0.47 (−0.34 to 1.29) p = 0.25
NAA 11.32 ± 1.46 11.38 ± 1.24 0.12 (−0.37 to 0.61) p = 0.64 11.50 ± 1.66 11.38 ± 1.24 0.23 (−0.29 to 0.74) p = 0.38
mI 6.09 ± 0.94 6.06 ± 0.96 0.02 (−0.34 to 0.38) p = 0.92 6.17 ± 1.16 6.06 ± 0.96 0.17 (−0.21 to 0.54) p = 0.38
iaDhD (n = 47) 
unadjusted 
mean ± sD
controls 
(n = 78) 
unadjusted 
mean ± sD
adjusted difference 
(95% ci)a
MancOVa test 
for difference 
(Wilks’ lambda 
test: p = 0.71)a
caDhDb 
(n = 57) 
unadjusted 
mean ± sD
controls 
(n = 78) 
unadjusted 
mean ± sD
adjusted difference 
(95% ci)a
MancOVa  
test for 
difference 
(Wilks’ lambda 
test: p = 0.67)a
cerebellum
Cre 9.21 ± 1.08 9.28 ± 0.81 0.06 (−0.30 to 0.42) p = 0.74 9.34 ± 1.24 9.28 ± 0.81 0.02 (−0.35 to 0.39) p = 0.91
t-Cho 2.28 ± 0.39 2.26 ± 0.27 0.07 (−0.06 to 0.19) p = 0.30 2.30 ± 0.30 2.26 ± 0.27 0.04 (−0.06 to 0.4) p = 0.42
Glx 10.88 ± 1.97 10.88 ± 1.22 −0.10 (−0.72 to 0.51) p = 0.74 10.69 ± 1.74 10.88 ± 1.22 −0.30 (−0.83 to 0.23) p = 0.27
NAA 8.98 ± 0.84 9.08 ± 0.68 −0.08 (−0.37 to 0.22) p = 0.61 9.08 ± 1.01 9.08 ± 0.68 −0.01 (−0.32 to 0.29) p = 0.93
mI 4.82 ± 0.84 4.99 ± 0.85 −0.14 (−0.48 to 0.20) p = 0.42 4.89 ± 0.91 4.99 ± 0.85 −0.06 (−0.38 to 0.26) p = 0.71
SD, standard deviation; CI, confidence interval; iADHD, inattentive ADHD subtype; cADHD, combined ADHD subtype; Cre, creatine; t-Cho, 
phosphorylcholine + glycerylphosphorylcholine; Glx, glutamate + glutamine; NAA, N-acetylaspartate; mI, myo-Inositol.
aMANCOVA, multivariate analysis of covariance using the covariates age, IQ, and nicotine consumption.
bThe hyperactive subtype was added to the combined subtype for all subtype analyses because of the small group size.
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